high throughput screening

Acrobat Genomics teaches AI to program biology using rapid, high-throughput experimental feedback measured directly within living human cells. Its AcrobaTx Engine is a closed-loop system for programmable biology in which AI proposes therapeutic candidates, designs are tested in parallel, functional data is measured from living human cells, and the data trains the next cycle's AI. The company develops genome editors and genetic medicines, and has completed DARPA Phase I research.

AI-guided protein engineeringfunctional measurement in living human cellsgenome editingmachine learning

Alltrna is the world's first tRNA platform company, deciphering tRNA biology and pioneering tRNA therapeutics to treat thousands of diseases. The company is advancing universal tRNA medicines to restore disrupted protein production, regardless of gene targeted, for diseases sharing the same underlying genetic mutation. Its platform incorporates AI/ML tools to develop and deliver diverse programmable molecules with broad therapeutic potential, including engineered tRNAs that read premature termination codons to treat Stop Codon Disease.

AI/ML toolsengineering tRNAsmachine learning to engineer tRNA oligonucleotidessynthesis of chemically modified tRNAstRNA platform

Alvus Health enables patient-derived epithelial organoids for high-throughput, multi-modal genetics-proteomics-histology phenotypic profiling for biopharmaceutical discovery. The company maintains a surrogate organ biobank covering intestinal, lung, stomach, cerebral, urinary, and ovarian tissues, and in March 2024 partnered with NASA, MGH, and SpaceTango to send organoids to space.

AI-enabled phenotypic analysiscell transfection for gene editinghigh-throughput automated organoid culturingmultiplex imagingorganoid culturingsequencing

AnalytiCon Discovery is a natural product research and development company providing expertise in natural product chemistry for novel pharmaceutical, cosmetic and nutritional products. It offers a technology platform and chemical space for drug discovery, and publishes research on natural products, screening and synthesis.

biocatalytic cascade reactionsmacrocyclic library generationmulti-gram synthesisnatural product research

APTAGEN Labs is a biotechnology and life-sciences company focused on synthetic biology, described as a global leader in developing DNA-based antibodies called aptamers, with over 30 years of experience. Aptamers are target-recognition elements with high affinity and specificity against small molecules, protein biomarkers, cells, and tissues, serving as an alternative to antibodies for diagnostic, therapeutic, and bio-industrial applications. Aptagen was formed in 2004, with operations beginning in 2006, and is located in Jacobus, PA.

AI-supported bioinformatics analysisaptamer R&DCD spectraFlow Cytometrygel-shift assayMicroscopymonoclonal aptamer synthesisNextGen sequencingoligonucleotide synthesisSELEX screening/selectionSPR

AROPHA is an independent testing laboratory established in 2021 in Cleveland, Ohio, accredited to ISO/IEC 17025:2017 and compliant with GLP requirements. It specializes in biodegradability, compostability, and ecotoxicity testing, supplemented by proprietary in-silico prediction capabilities through its ArophaAI platform. The company serves over 150 organizations worldwide and combines predictive modeling with laboratory automation.

biodegradability testingcompostability testingecotoxicity testingGLP compliant testingin silico testingISO/IEC 17025:2017 accredited testinglaboratory automationpredictive modeling

Arrayjet is a microarray company based in Edinburgh, Scotland, providing microarray instruments, contract research and contract manufacturing services. It developed and patented an inkjet technology to print biological samples onto solid substrates to create microarrays. Its Mercury microarray spotters use piezoelectric inkjet printheads for ultra-low-volume dispensing. Operations run from an ISO 13485:2016 accredited facility, and instruments are installed across 5 continents.

Bioinformaticscontract manufacturinginkjet microarray printingISO 13485:2016 quality managementmicroarray assay developmentpiezoelectric inkjet printingsample preparationultra-low-volume dispensing

BioAscent is a provider of integrated drug discovery services based at the former Organon/MSD R&D site in Newhouse, Scotland, UK. Founded in 2013, its services include assay development, target analysis, compound screening, medicinal and synthetic chemistry, computational chemistry, DMPK, protein science and compound management, with access to in-house diversity and fragment libraries.

assay developmentbiophysicscompound managementcompound screeningcompound storage and logisticscomputational chemistryDMPKin silico discoveryLC-MSliquid handlingmedicinal chemistryNMRprotein productionpurificationstructural biologysurface plasmon resonancesynthetic chemistry

BioCopy AG is a multinational biotechnology company headquartered in Basel, Switzerland, with an R&D facility in Emmendingen, Germany. Founded in 2019, it combines antibody engineering with data science and AI in an integrated wet-lab and digital discovery model to unlock challenging intracellular cancer targets and develop next-generation TCR(m)-based immunotherapeutics.

AI-driven predictionantibody engineeringantibody lead discoveryantibody lead optimizationstructural modelingtarget credentialingwet-lab validation

Broad Capabilities. Boutique Services. Every program deserves a partner, not just a provider. We built Bio Duro to be exactly the right size: broad enough to support your science at every stage, agile enough to move when you need to move, and focused enough to treat your program like the priority it is. Explore Our Capabilities All Company News October 1, 2026 June 6, 2026 May 28, 2026 April 28, 2026 April 23, 2026 March 12, 2026 March 3, 2026 February 10, 2026 January 27, 2026 November 18, 2025 August 20, 2025 July 30, 2025 June 10, 2025 May 8, 2025 April 7, 2025 March 25, 2025 March 5, 2025 January 20, 2025 January 9, 2025 January 6, 2025 October 24, 2024 October 1, 2024 September 16, 2024 All Company News Deliver solutions using enabling technologies like AI enabled molecular design, high throughput screening, DNA-coded library, parallel synthesis. Explore Chemistry Most visited.

AI-assisted molecular designanalytical chemistryAPI manufacturingbioanalysiscomputational chemistryDMPKDNA-encoded library screeningdrug product manufacturingformulation developmentin vitro assaysin vivo modelsmedicinal chemistryparallel synthesispeptide chemistryprocess R&DScale upsynthetic chemistrytoxicology

Thank you! Your submission has been received!Oops! Something went wrong while submitting the form.We Are Revolutionizing Plastic Recycling We are an AI native company developing engineered enzymes that act as ‘molecular scissors” to recycle plastic, enabling manufacture of economical, 100% recycled plastic products in a circular economy.Contact Us We Are Revolutionizing Plastic Recycling Birch Biosciences is developing novel plastic recycling technologies using generative AI and advanced enzyme engineering to bring plastics into the circular economy.Contact Us9% Of Plastic Is Recycled.We’re Fixing That.The 9% US plastic recycling rate hasn’t improved in 15 years. Most recycled plastic is lower quality and higher cost than virgin plastic manufactured from fossil fuels. Today, manufacturing new plastic is responsible for 7% of global carbon emissions.Learn moreabout us Our technology OUR.

enzymatic recyclingenzyme engineeringgenerative AIplastic depolymerizationrepolymerization

BrainXell is an industry leading producer of high-purity, iPSC-derived human neurons and glia for research and development, with a focus on drug discovery and CNS disease modeling. The company provides human-derived iPSC neurons, astrocytes, microglia, and other cell models, and states it is trusted by more than 75% of the world's largest pharmaceutical companies.

3-D neural spheroidsassay servicescalcium assayscustom differentiationelectrophysiologyhigh content analysisiPSC reprogrammingviability/cytotoxicity assays

Cryptyx Bioscience is a drug discovery company in Princeton, NJ whose platform provides a rapid, efficient approach for activating silent biosynthetic gene clusters and unearthing potential leads that cannot be accessed with extant technologies. The platform does not require complex genetic, cloning, or culturing procedures, can be used with sequenced and unsequenced bacteria, and reports on the bioactivity of cryptic metabolites. The company is advancing novel therapies for bacterial and viral pathogens and expanding R&D to oncology.

activating silent biosynthetic gene clustersdrug discovery platformHiTES platformmicrobial culture growth and maintenancenatural product isolation and structure elucidationphenotypic biological assays

EnquBio Inc is a San Diego-based drug R&D technology and service company (preclinical CRO) that advances pharmaceutical and biotechnology research through a comprehensive suite of drug discovery solutions. Located in San Diego's biotech hub, it operates state-of-the-art facilities led by an industry-recognized team, offering expertise in exploratory biology, high-throughput screening, SAR studies, in vitro and in vivo pharmacology, immunology-focused studies, biomarker discovery, and clinical sample analysis.

assay developmentbioanalysisbiomarker discoverycell line generationex vivo pharmacologygene expression analysisgenome editinghigh-content screeningimmunoassayimmunophenotypingin vivo imagingin vivo pharmacologyiPSC platformnon-GLP toxicologyPK/PD analysisWestern blot

Enzymlogic is an analytical contract research organization (CRO) specializing in binding kinetic profiling of compounds for drug discovery. It focuses on the Hit to Lead and Lead Optimization stages, using kinetic profiling assays to identify reversible and irreversible compounds with therapeutic potential. Its patented kinetic screening platform delivers compound-target interaction data such as Kd, kon, koff and residence time, and its COVALfinder platform characterizes binding mechanisms of reversible, reversible covalent and irreversible drugs.

assay developmentbinding kinetics analysiskinetic profilingprotein science

Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in the Bay Area developing transformative technology platforms that can access cancer-specific targets and harness the evolutionary power of T cells for the treatment of solid tumors and other malignancies. Its mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

antibody developmentclinical developmentCMC/manufacturingT-cell therapy development

Exobiosphere uses microgravity as a new dimension for biology to accelerate drug discovery and unlock therapies that are hard or impossible to develop on Earth. It is building a standardized space-based high-throughput testing platform, the Orbital High-Throughput Screening in Microgravity (OHTS) system, allowing pharma and biotech partners to run automated experiments in orbit at scale, combining microgravity with lab automation and bioinformatics.

Bioinformaticsdata analysislab automationmicrogravity-based disease modelingpayload designspace systems engineering

Forta Bio is a private, California-based biotech developing ODC™ (Oligonucleotide-Dependent Cytotoxicity), a therapeutic class it created to selectively eliminate pathogenic cells while aiming to preserve healthy immunity. Built on foundational research at City of Hope and supported by multi-million-dollar grant funding, its platform spans oncology (FortaOnc™), autoimmune disease (FortaReg™), and aptamer-targeted delivery (FortaApt™), supported by its internal screening and optimization engine FortaGuideAI.

aptamer-targeted deliverydrug developmentgenerative multi-objective optimizationin vivo studiesoligonucleotide therapeutics

IRBM is a preclinical drug discovery organization based in Rome, Italy, conducting small molecule, peptide and antibody programs from target validation through to a preclinical candidate, either as a full integrated program or as a single capability for clients. Its scientists have contributed to three approved drugs and delivered more than thirty preclinical candidates to partners.

ADMEantibody phage displayassay developmentBioinformaticsbiophysical characterizationcompound managementcomputational chemistryDMPKfunctional genomicshigh-content screeningin vivo pharmacologymedicinal chemistrymRNA displayNMRpeptide chemistrypeptide phage displayprotein productionstructural biologysynthetic chemistry